Conventional biomarkers, including PD-L1, microsatellite status, and tumor mutational burden (TMB), are insufficient and sometimes incompetent in predicting the therapeutic outcomes of ICIs [10,11,12,13,14]. The gene discussed is CD274; the disease is neoplasm.